Hyperactivation of CDK1 is associated with poor prognosis for patients with lung adenocarcinoma (Shi et al., 2016), ovarian cancer (Yang et al., 2016), renal cell carcinoma(Hongo et al., 2014), and breast cancer (Pavlou et al., 2014). This evidence concerns the gene CDK1 and renal cell carcinoma.